Fonterra has agreed to divest its 51 percent stake in two joint venture farms in Shandong province, China, to Singapore-based AustAsia Investment Holdings for $62.1 million.
The farms will be sold to Singapore-based AustAsia for $115.5 million.
Fonterra, which has decided to prioritize producing New Zealand milk, has completed selling its wholly-owned China farming hubs.
Fonterra CEO, Miles Hurrell, acknowledged that Greater China is among their most important and strategic markets and would bring the goodness of New Zealand milk to Chinese customers in innovative ways and by partnering with local Chinese companies.
The sale of the JV farms, which requires no further regulatory approvals, is expected to be completed on June 30.


Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Asian Stocks Rise as Wall Street Tech Rally Lifts Markets, Yen Slumps Despite BOJ Rate Hike
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Wall Street Ends Higher as S&P 500, Nasdaq Extend Gains Ahead of Holiday Week
UK Economy Grows 0.1% in Q3 2025 as Outlook Remains Fragile
FDA Approves Mitapivat for Anemia in Thalassemia Patients
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks
US and Japan Fast-Track $550 Billion Strategic Investment Initiative
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist
Gold Prices Surge to Record Highs as Geopolitical Tensions Fuel Safe-Haven Demand
Oil Prices Edge Higher as Strong U.S. Growth and Supply Risks Support Market
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
UBS Warns of Short-Term Risks as Precious Metals Rally to Record Highs
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 



